• Journal of Inorganic Materials
  • Vol. 37, Issue 4, 361 (2022)
MXenes schematic composition[14]
1. MXenes schematic composition[14]
Schematic preparation methods for MXenes and products prepared by chemical vapor deposition
2. Schematic preparation methods for MXenes and products prepared by chemical vapor deposition
(a) Schematic diagrams of Ti3C2 nanoparticles on PTT in 4T1 tumor bearing nude mice[30] and (b) Nb2C nanosheets for PTT in vivo under NIR-I and NIR-II[28]
3. (a) Schematic diagrams of Ti3C2 nanoparticles on PTT in 4T1 tumor bearing nude mice[30] and (b) Nb2C nanosheets for PTT in vivo under NIR-I and NIR-II[28]
Schematic diagrams of (a) Ti3C2 nanomaterials loaded with DOX for tumor PTT/PDT/CHEMO combined therapy[29], (b) DOX@Ti3C2-SP nanomaterials for tumor PTT/CHEMO combined therapy[32], and (c) Ti3C2@Met@CP nanomaterials for tumor PTT/PDT/CHEMO combined therapy[57]
4. Schematic diagrams of (a) Ti3C2 nanomaterials loaded with DOX for tumor PTT/PDT/CHEMO combined therapy[29], (b) DOX@Ti3C2-SP nanomaterials for tumor PTT/CHEMO combined therapy[32], and (c) Ti3C2@Met@CP nanomaterials for tumor PTT/PDT/CHEMO combined therapy[57]
Schematic illustrations for (a) combined therapy on HCC cells as assisted by DOX@Ti3C2@mMSNs-RGD at the cell level[58], (b) CTAC@Nb2C-MSN-PEG-RGD composite nanomaterials releaseing CTAC under the action of PTT for combined treatment of tumor[59], (c) AIPH@Nb2C@Si composite nanomaterials generating free radicals under the action of PTT[60], and (d) Nb2C-MSNs-SNO composite nanomaterials releasing NO under the action of PTT for combined treatment of tumor[61]
5. Schematic illustrations for (a) combined therapy on HCC cells as assisted by DOX@Ti3C2@mMSNs-RGD at the cell level[58], (b) CTAC@Nb2C-MSN-PEG-RGD composite nanomaterials releaseing CTAC under the action of PTT for combined treatment of tumor[59], (c) AIPH@Nb2C@Si composite nanomaterials generating free radicals under the action of PTT[60], and (d) Nb2C-MSNs-SNO composite nanomaterials releasing NO under the action of PTT for combined treatment of tumor[61]
Schematic diagrams of (a) MnOx/Ti3C2[64], (b) Ta4C3-IONP[62], (c) MIG[65], (d) GdW10@Ti3C2[66], and (e) Ti3C2@Au[67] composite nanomaterials in tumor theranostics
6. Schematic diagrams of (a) MnOx/Ti3C2[64], (b) Ta4C3-IONP[62], (c) MIG[65], (d) GdW10@Ti3C2[66], and (e) Ti3C2@Au[67] composite nanomaterials in tumor theranostics
Schematic diagrams of the application of MXenes nanomaterials in (a) biosensing[81] and (b) bone tissue engineering[82]
7. Schematic diagrams of the application of MXenes nanomaterials in (a) biosensing[81] and (b) bone tissue engineering[82]
Preparation methodAdvantagesDisadvantagesRef.
HF acid etchingSimpleUsing highly corrosive and harmful HF[11]
Fluoride saltMilder reaction conditions; Safer than that of HF acid etchingDifficult to prepare nitride MXenes[36-37]
Molten saltPreparing nitride MXenes and preparing MXenes through non-MAX materialsRequiring inert protective gas, under high temperature condition[19,38]
Alkali assisted hydrothermalPreparing MXenes without fluorine functional groupsHigh concentration of NaOH, requiring inert protective gas, under high temperature condition[39]
Chemical vapor depositionPrecise controlling element composition, size and surface groupsDifficult to prepare large-sized MXenes[41]
Table 1. Summary of preparation methods of MXenes
MXenes materialFirst report time NIR range Wavelength /nm Extinction coefficient/(L·g-1·cm-1) Photothermal conversion efficiency/%NIR power /(W·cm-2) Irradiation time /min Temperature range/℃ Ref.
Ti3C22016/10NIR-I80825.2-0.8523.5-60.054
Nb2C 2017/10NIR-I80837.636.51.5525.0-60.028
NIR-II106435.446.651.5525.0-60.0
Ta4C32017/11NIR-I8088.6734.92.0532.5-65.0[27]
Ti2C 2019/01NIR-I8087.3987.12.0225.5-93.8[48]
Mo2C 2019/04NIR-I80818.024.51.01025.0-57.8[49]
NIR-II106412.343.31.01025.0-62.3
V2C 2020/01NIR-I80838.348.50.481024.0-57.9[50]
Ti2N 2020/11NIR-I80841.2548.621.0525.0-60.0[51]
NIR-II106434.9245.511.0525.0-60.0
Table 2. First application of MXenes in PTT on tumor
MXenesReport timeCell linesTreatment strategy Diagnosis strategy Molecule for targeting Ref.
Ti3C22016/104T1PTT--[54]
Ti3C2-SP 2016/124T1PTT--[30]
MnOx/Ti3C2-SP 2017/084T1PTTPA/MR-[64]
Nb2C-PVP 2017/104T1PTTPA-[28]
Ti3C22017/10HeLa/MCF-7/U251/HEK293PTTPA-[68]
Ti3C2-DOX 2017/11HCT-116PTT/PDT/CHEMO-HA[29]
MnOx/Ta4C3-SP 2017/114T1PTTMR/CT/PA-[27]
Ta4C3-SP 2017/124T1PTTPA/CT-[69]
GdW10@Ti3C22018/014T1PTTCT/MR-[66]
DOX@Ti3C2-SP 2018/024T1PTT/CHEMOPA-[32]
Ta4C3-IONP-SP 2018/024T1PTTCT/MR-[62]
DOX@Ti3C2@mMSNs- RGD 2018/04SMMC-7721PTT/CHEMO-RGD[58]
CTAC@Nb2C-MSN-PEG-RGD 2018/08U87PTT/CHEMOPARGD[59]
Ti3C2@Au 2018/124T1PTT/RTPA/CT-[67]
A@Nb2C@Si 2019/014T1PTT/CHEMOPA-[60]
Ti2C 2019/01A375/HaCaT/MCF-7/MCF-10APTT--[48]
Mo2C 2019/044T1PTT--[49]
Mo2C@C 2019/04HepG2/HUVEC/IOSE80PTT/PDTPA/CT-[70]
Au/Ti3C22019/06MCF-7PTT--[71]
Au/Fe3O4/Ti3C22019/06MCF-7PTT--[71]
MIG(Ti3C2-IONP@PEG-GOD) 2019/104T1PTT/CHEMOMR-[65]
Nb2C-MSNs-SNO 2019/114T1PTT/CHEMOPA-[61]
Ti2N 2019/11MCF-7/A365/MCF-10A/HaCaTPDT--[72]
V2C 2020/01MCF-7PTT--[50]
TO-MX(Ti3C2/Ti2O3) 2020/02A375/HaCaT/MCF-7/MCF-10APDT--[73]
PVP/Nb2C 2020/044T1PTT--[74]
Nb2C/zein 2020/044T1PTT--[75]
NMQDs-Ti3C2Tx2020/04ADSCs/HeLa/MCF-7PDT/CHEMO--[76]
Nb2C/PLL 2020/05A375/HaCaTPDT--[77]
Nb4C3/PLL 2020/05A375/HaCaTPDT--[77]
Ti3C2@Met@CP 2020/06MDA-MB-231PTT/PDT/CHEMO--[57]
DOX@Ti3C2-CoNWs 2020/064T1PTT/CHEMO--[78]
Ti3C2/CA4@PLEL 2020/064T1/HUVECsPTT/CHEMO--[79]
Ti2N 2020/114T1/U87/293TPTTPA-[51]
MXene(Ti3C2)-DOX 2021/01HeLaPTT/PDT/CHEMO--[80]
Table 3. MXenes for application in tumor theranostics